New Frontier Health Corp

The only substantive difference recoverable from this extract is the Adjusted EBITDA bridge itself, and it is a wider one: the November definition adds back IFRS 16 lease expense and transaction costs on top of the shareholder fees, so an Adjusted EBITDA figure in this deck is not computed on the same basis as one in the September deck and the two should not be compared directly. The slides, and any figures on them, are outside the captured text. This is the Form 8-K copy of a deck also filed the same day as definitive additional proxy materials.

The only substantive difference recoverable from this extract is the Adjusted EBITDA bridge itself, and it is a wider one: the November definition adds back IFRS 16 lease expense and transaction costs on top of the shareholder fees, so an Adjusted EBITDA figure in this deck is not computed on the same basis as one in the September deck and the two should not be compared directly. The slides, and any figures on them, are outside the captured text. The same deck was furnished the same day on a Form 8-K; filing it as DEFA14A is what puts it into the proxy record for the stockholder vote.

This is the first period-level check of the target against the projections already in the deal record, and it is mixed on its own terms: revenue growth of 21.8% is running ahead of the 21.5% full-year projection, but Adjusted EBITDA of RMB 84 million against a projected RMB 140 million is 60% of the year in the first half, so the second half carries the larger share.

This is the first period-level check of the target against the projections already in the deal record, and it is mixed on its own terms: revenue growth of 21.8% is running ahead of the 21.5% full-year projection, but Adjusted EBITDA of RMB 84 million against a projected RMB 140 million is 60% of the year in the first half, so the second half carries the larger share.

The trust is the smallest piece of the funding. The purchase price is met from trust proceeds after redemptions plus $190,000,000 from forward purchase agreements with anchor investors, the RMB equivalent of $300,000,000 from a new seven-year senior secured credit facility, up to $711,481,860 of PIPE subscriptions, and $159,000,000 of seller and management re-investment and equity rollover. Because the price is fixed in cash, redemptions change the funding mix rather than the price. The meeting date and time are left blank in this preliminary version.

The mechanical facts available from this extract are that the target reports under IFRS rather than US GAAP, and that its headline profitability measure is adjusted for management fees paid to Fosun and TPG — an add-back that only exists because those fees are related-party charges expected not to survive the transaction. The presentation's substantive slides, including any projections it contains, are outside the captured text, so nothing here states deal consideration, valuation or timing.

This is the 8-K half of a same-day pair — the presentation is furnished under the Exchange Act here and filed as proxy soliciting material under the DEFA14A, which is the ordinary mechanism for a deck used in a merger solicitation. The only substantive terms recoverable from the captured text are the accounting ones: IFRS reporting, and an Adjusted EBITDA whose add-backs include related-party management fees to Fosun and TPG.

Paid-in capital is exhausted, so the $5,000,001 net tangible asset floor now rests entirely on retained earnings — and this is the quarter in which the United Family Healthcare agreement was signed.

Sizes the target: roughly RMB 2.5 billion of expected 2019 revenue against an announced $1,440 million enterprise value. The revenue figure is a forecast for the current year, not a reported result.

The same call filed under Item 7.01; the target's scale figures are identical and are current-year forecasts rather than reported results.

Names New Frontier's target — the Healthy Harmony group — and identifies a purchase structure with buyer financial-capability and support-agreement representations, meaning committed money beyond the trust is part of the deal. The extracted text is the agreement's table of contents; the purchase price and closing conditions are in sections not reproduced here.

The financing is layered so that redemptions barely matter: $711 million of committed equity at $10.00, a $90 million non-redemption commitment and a $300 million debt facility sit behind a $478 million trust — the deal is not funded out of the trust in any meaningful sense.

Puts the signed agreement into the proxy record. The extracted text is the table of contents, not the purchase price.

Nine months from the July 2018 IPO's 24-month deadline clock, this SPAC still holds nearly $2 million of cash outside the trust — unusual head-room among this cohort.

Sizes the forward purchase commitments at $181,000,000 — capital contracted to arrive at closing — and shows the sponsor's promote being reduced proportionately because they came in below the $200 million target.

First reported balance for the $10.00 trust of about $289 million, with an unusually large $2.7 million of cash outside it — the working capital available before any sponsor loan is needed.

A pre-IPO period: the $7.75 million private placement money was already in hand but held as a segregated deposit, and the Class A shares and trust do not appear until the following quarter.

Fixes a $10.00 trust and a 24-month deadline running from July 3, 2018, with $6,912,500 of deferred underwriting payable out of the trust at any closing.